Fig 1: SR-B1 partly contributes to uptake of mycolactone in monocytes. (A) SR-B1 expression as measured by flow cytometry in human blood T cells (T), B cells or monocytes (Mono) compared to isotype labeling (Iso). Data are shown as mean fluorescence intensities (MFI) normalized to cell size (FCS corrected). (B) Incorporation of Bdpy-ML into purified human primary monocytes after 1 h in presence of vehicle or of the BLT inhibitors: BLT-1 (10 µM), BLT-4 (75 µM), and BLT-5 (150 µM). Data are shown as percentage of uptake to control (vehicle) and are means ± SD of triplicates. Test one-way Anova, *p < 0.1. (C) Incorporation of Bdpy-ML into undifferentiated THP-1 cells after 1 h in presence of vehicle (Veh) or BLT-4 (75 µM). Gate on viable cells. Data are shown as percentage of uptake to control (Veh) and are means ± SD of 3 independent experiments. Test Mann-Whitney, ****p < 0.0001. (D) SR-B1 expression in non-transduced cells (UT), cells transduced with non-targeting siRNA (Ctrl) or with SR-B1 siRNA (siRNA). Data are expressed as percentage to control and are means ± SD of 3 independent experiments with at least 2 replicates per group. (E) Bdpy-ML uptake in non-transduced (NT) or transduced THP-1 cells with non-targeting siRNA (Ctrl) or with SR-B1 siRNA (siRNA), after 1 or 24 h of incubation with Bdpy-ML. Data are means ± SD of 3 independent experiments with at least 2 replicates per group, expressed as percentage to control. Test Mann-Whitney, *p < 0.1, **p < 0.01, ***p < 0.001.